{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:07:43Z","timestamp":1761584863925,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.atherosclerosissup.2019.08.045","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T11:38:00Z","timestamp":1575632280000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Experience with proprotein convertase subtilisin\/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis"],"prefix":"10.1016","volume":"40","author":[{"given":"Sergey","family":"Tselmin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Julius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Weinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1567-5688(09)71803-3","article-title":"The Dresden Apheresis Center \u2013 experience with LDL apheresis and immunoadsorption","volume":"10","author":"Julius","year":"2009","journal-title":"Atherosclerosis Suppl"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14779072.6.5.629","article-title":"Comparison of different LDL apheresis methods","volume":"6","author":"Julius","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2017.05.012","article-title":"How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - estimates form a large single center","volume":"30","author":"Hohenstein","year":"2017","journal-title":"Atherosclerosis Suppl"},{"issue":"16","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib6","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"Engl J Med"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib7","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosissup.2012.10.001","article-title":"The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease","volume":"14","author":"Thompson","year":"2013","journal-title":"Atherosclerosis Suppl"},{"issue":"24","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib9","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib10","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 Years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cyto.2011.08.027","article-title":"Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia","volume":"56","author":"Stefanutti","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.atherosclerosissup.2015.02.016","article-title":"Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters. A comparison of two different apheresis techniques","volume":"18","author":"Kopprasch","year":"2015","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jca.20285","article-title":"Lipid-apheresis improves microcirculation of the upper limbs","volume":"26","author":"Rossenbach","year":"2011","journal-title":"J\u00a0Clin Apher"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-integrating lipoprotein and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"issue":"39","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib15","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/clp.13.68","article-title":"Lipoprotein apheresis: an update","volume":"8","author":"Julius","year":"2013","journal-title":"Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s15027-017-1273-z","article-title":"Lipoproteinapherese: \u201eNebenwirkung\u201c wandelt sich in einen Vorteil","author":"Tselmin","year":"2017","journal-title":"Cardiovasc"},{"issue":"7","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib18","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.atherosclerosissup.2015.02.028","article-title":"Effects of lipoprotein apheresis on PCSK9 levels","volume":"18","author":"Julius","year":"2015","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosissup.2015.02.018","article-title":"Effects of different lipoprotein apheresis methods on serum protein levels","volume":"18","author":"Julius","year":"2015","journal-title":"Atherosclerosis Suppl"},{"issue":"48","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib21","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosissup.2015.02.033","article-title":"Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run","volume":"18","author":"Gro\u00df","year":"2015","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib23","first-page":"3321","article-title":"Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Richtlinie Methoden vertrags\u00e4rztliche Versorgung: apherese bei isolierter Lp(a)-Erh\u00f6hung","volume":"138","author":"Bundesministerium f\u00fcr Gesundheit","year":"2008","journal-title":"BAnz"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacl.2018.02.014","article-title":"Relationship between \"LDL-C\", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide","volume":"12","author":"Viney","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib25","doi-asserted-by":"crossref","unstructured":"Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Lipoprotein(a) and proprotein convertase subtilisin\/kexin type 9 inhibitors. Clin Res Cardiol Suppl.\u00a0https:\/\/doi.org\/10.1007\/s11789-019-00099-z.","DOI":"10.1007\/s11789-019-00099-z"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1526-0968.2001.00359.x","article-title":"Current topics on low-density lipoprotein apheresis","volume":"5","author":"Bambauer","year":"2001","journal-title":"Ther Apher"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2019.08.045_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1526-0968.2003.00120.x","article-title":"State of the art of low-density lipoprotein apheresis in the year 2003","volume":"8","author":"Bosch","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2019.08.045_bib28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosissup.2017.05.047","article-title":"Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - a multicenter observational study","volume":"30","author":"Schatz","year":"2017","journal-title":"Atherosclerosis Suppl"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568819300686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568819300686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:02:18Z","timestamp":1761584538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568819300686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"alternative-id":["S1567568819300686"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2019.08.045","relation":{},"ISSN":["1567-5688"],"issn-type":[{"type":"print","value":"1567-5688"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with proprotein convertase subtilisin\/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2019.08.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}